Bank of New York Mellon Corp lessened its stake in TherapeuticsMD Inc (NASDAQ:TXMD) by 12.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,149,690 shares of the company’s stock after selling 2,994,936 shares during the period. Bank of New York Mellon Corp owned 8.77% of TherapeuticsMD worth $54,990,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently bought and sold shares of TXMD. Moors & Cabot Inc. purchased a new position in TherapeuticsMD in the second quarter valued at about $25,000. Moloney Securities Asset Management LLC purchased a new position in TherapeuticsMD in the second quarter valued at about $27,000. H D Vest Advisory Services purchased a new position in TherapeuticsMD in the second quarter valued at about $34,000. Advisor Group Inc. grew its stake in TherapeuticsMD by 73.2% in the second quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock valued at $36,000 after purchasing an additional 5,900 shares during the last quarter. Finally, Aperio Group LLC grew its stake in TherapeuticsMD by 87.0% in the second quarter. Aperio Group LLC now owns 29,593 shares of the company’s stock valued at $77,000 after purchasing an additional 13,771 shares during the last quarter. Institutional investors own 78.88% of the company’s stock.
Shares of NASDAQ TXMD opened at $3.42 on Friday. The company has a debt-to-equity ratio of 24.29, a quick ratio of 4.99 and a current ratio of 5.17. The company has a market cap of $824.98 million, a PE ratio of -5.80 and a beta of 1.70. The business has a 50-day simple moving average of $2.67 and a two-hundred day simple moving average of $3.56. TherapeuticsMD Inc has a fifty-two week low of $1.82 and a fifty-two week high of $6.94.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The business had revenue of $6.08 million during the quarter, compared to analyst estimates of $5.12 million. TherapeuticsMD had a negative return on equity of 212.57% and a negative net margin of 913.07%. TherapeuticsMD’s revenue was up 60.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.15) EPS. On average, sell-side analysts predict that TherapeuticsMD Inc will post -0.73 earnings per share for the current fiscal year.
Several equities analysts have issued reports on TXMD shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of TherapeuticsMD in a research note on Wednesday, August 7th. Jefferies Financial Group cut their target price on TherapeuticsMD from $4.00 to $3.00 and set a “hold” rating on the stock in a research note on Monday, July 15th. Cowen cut their target price on TherapeuticsMD from $16.00 to $9.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 11th. Noble Financial reiterated a “buy” rating and issued a $13.00 target price on shares of TherapeuticsMD in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. cut their target price on TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, June 11th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $9.16.
In other TherapeuticsMD news, Director Angus C. Russell purchased 35,000 shares of the stock in a transaction on Thursday, August 15th. The stock was acquired at an average price of $2.83 per share, with a total value of $99,050.00. Following the completion of the acquisition, the director now owns 73,500 shares in the company, valued at $208,005. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Robert G. Finizio purchased 52,405 shares of the stock in a transaction on Friday, August 9th. The stock was acquired at an average cost of $2.96 per share, with a total value of $155,118.80. Following the acquisition, the chief executive officer now owns 18,166,559 shares of the company’s stock, valued at approximately $53,773,014.64. The disclosure for this purchase can be found here. In the last three months, insiders acquired 170,549 shares of company stock valued at $493,167. Corporate insiders own 18.91% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women’s health care product company in the United States. The company’s hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Recommended Story: What are retained earnings?
Want to see what other hedge funds are holding TXMD?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TherapeuticsMD and related companies with MarketBeat.com’s FREE daily email newsletter.